These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 27468685)

  • 21. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.
    Grignani F; Testa U; Rogaia D; Ferrucci PF; Samoggia P; Pinto A; Aldinucci D; Gelmetti V; Fagioli M; Alcalay M; Seeler J; Grignani F; Nicoletti I; Peschle C; Pelicci PG
    EMBO J; 1996 Sep; 15(18):4949-58. PubMed ID: 8890168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A role for PML and the nuclear body in genomic stability.
    Zhong S; Hu P; Ye TZ; Stan R; Ellis NA; Pandolfi PP
    Oncogene; 1999 Dec; 18(56):7941-7. PubMed ID: 10637504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells.
    Müller S; Miller WH; Dejean A
    Blood; 1998 Dec; 92(11):4308-16. PubMed ID: 9834237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B.
    Wang C; Su L; Shao YM; Chen WZ; Bu N; Hao R; Ma LY; Hussain L; Lu XY; Wang QQ; Naranmandura H
    Toxicol Appl Pharmacol; 2019 Dec; 384():114775. PubMed ID: 31669778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repression of CDKN2C caused by PML/RARα binding promotes the proliferation and differentiation block in acute promyelocytic leukemia.
    Wang X; Tan Y; Li Y; Li J; Jin W; Wang K
    Front Med; 2016 Dec; 10(4):420-429. PubMed ID: 27888400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low HOX gene expression in PML-RARα-positive leukemia results from suppressed histone demethylation.
    Rejlova K; Musilova A; Kramarzova KS; Zaliova M; Fiser K; Alberich-Jorda M; Trka J; Starkova J
    Epigenetics; 2018; 13(1):73-84. PubMed ID: 29224413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
    Misra S; Selvam AK; Wallenberg M; Ambati A; Matolcsy A; Magalhaes I; Lauter G; Björnstedt M
    Oncotarget; 2016 Nov; 7(46):74686-74700. PubMed ID: 27732960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Skp2 promotes APL progression through the stabilization of oncoprotein PML-RARα and the inhibition of JunB expression.
    Dan W; Zhong L; Yu L; Xiong L; Li J; Ye J; Luo X; Liu C; Chu X; Liu B
    Life Sci; 2022 Jan; 289():120231. PubMed ID: 34921867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. UBE1L represses PML/RAR{alpha} by targeting the PML domain for ISG15ylation.
    Shah SJ; Blumen S; Pitha-Rowe I; Kitareewan S; Freemantle SJ; Feng Q; Dmitrovsky E
    Mol Cancer Ther; 2008 Apr; 7(4):905-14. PubMed ID: 18413804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
    Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
    Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As
    Huang X; Yang Y; Zhu D; Zhao Y; Wei M; Li K; Zhu HH; Zheng X
    Cell Mol Life Sci; 2022 May; 79(6):319. PubMed ID: 35622143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ATPR induces acute promyelocytic leukemia cells differentiation and cycle arrest via the lncRNA CONCR/DDX11/PML-RARα signaling axis.
    Liu S; Zhan W; He X; Hao M; Shen W; Zhang X; Wang M; Li Z; Hou R; Ou Z; Feng Y; Chen F
    Gene; 2024 Jul; 917():148443. PubMed ID: 38582263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The promyelocytic leukemia protein stimulates SUMO conjugation in yeast.
    Quimby BB; Yong-Gonzalez V; Anan T; Strunnikov AV; Dasso M
    Oncogene; 2006 May; 25(21):2999-3005. PubMed ID: 16501610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells.
    Duprez E; Lillehaug JR; Gaub MP; Lanotte M
    Oncogene; 1996 Jun; 12(11):2443-50. PubMed ID: 8649786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.
    Kelly LM; Kutok JL; Williams IR; Boulton CL; Amaral SM; Curley DP; Ley TJ; Gilliland DG
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8283-8. PubMed ID: 12060771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
    Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H
    J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
    Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.
    Liu X; Yuan H; Peres L; Chen S; Chen Z; de The H; Zhou J; Zhu J
    PLoS One; 2014; 9(8):e104906. PubMed ID: 25119106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.